IROP
IRREGULARITY ON NOTICE OF POSSIBLE OPPOSITION RECEIVED FROM IB
28/07/2026
Voltar para busca
Dado oficial do USPTO
MULTIGEN
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
MULTIGEN
ST13
US500000079404951Classe
1, 5, 35, 42
Pedido
79404951
Registro
8182066
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
34
Atualização mais recente
28/07/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 35, 42
Data de depósito
09/07/2024
Data de registro
24/03/2026
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
24/03/2026
Última transação
28/07/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
BE
Examinador
SWEENEY, MOLLY B
Unidade examinadora
N30
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
Confo Therapeutics NV
Confo Therapeutics N.V.
Representantes
Jessica S. Sachs Harness, Dickey & Pierce, P.L.C.
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 35Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Laboratory chemicals for scientific use; biochemicals for in vitro and in vivo scientific use; biochemical substancesantibodies for stabilization of proteinsall the aforementioned substances for scientific use and for use in laboratories; reagents for medical research; diagnostic preparations for scientific or research use; chemical reagents for use in genetic research; receptors and reagents for testing for G protein-coupled receptors (GPCRs); chemical substances for use in the production of drugs; biochemical and chemical substances and chemical reagents for measuring combined or divided natural and non-natural G protein-coupled receptors (GPCRs); Proteins for use in science; chimeric proteins to measuretest and develop compounds and ligands binding to G protein-coupled receptors (GPCRs); none of the foregoing for vitamin supplementsfor vitamin supplements or generic pharmaceuticals dispensed by prescriptionfor vitamin supplements or generic pharmaceuticals distributed to pharmacies or wholesale distributors selling to pharmacies
Classe 5
chemical and biochemical substances for pharmaceutical or veterinary use screened by means of stabilized proteinssmall molecules and antibodies for use in oncology and immunology and for inflammatoryinfectiongastro-intestinalcardiovascularpulmonaryneurologicalmetabolicsystemicgynecologicalurologicaldermatologicalmusculo-skeletal treatment and treatment of orphan diseases; veterinary productsantigens and reagents for use in oncology and immunology and for inflammatoryinfectiongastro-intestinalcardiovascularpulmonaryneurologicalmetabolicsystemicgynecologicalurologicaldermatologicalmusculo-skeletal treatment and treatment of orphan diseases; none of the foregoing for vitamin supplementsfor vitamin supplements or generic pharmaceuticals dispensed by prescriptionfor vitamin supplements or generic pharmaceuticals distributed to pharmacies or wholesale distributors selling to pharmacies
Classe 35
Collating of data in computer databases; computerized file management; data processing; automated processing of medical and pharmaceutical data; compilation of statistical data relating to medical research and development; computer database management; none of the foregoing services for vitamin supplementsfor vitamin supplements or generic pharmaceuticals dispensed by prescriptionfor vitamin supplements or generic pharmaceuticals distributed to pharmacies or wholesale distributors selling to pharmacies
Classe 42
Medical and pharmacological research services; pharmaceutical drug development services; laboratory research services relating to pharmaceuticals; research and development of vaccines and medicines; scientific research for medical purposes and the development of pharmaceutical preparations in the area of drugs interacting with G protein-coupled receptors (GPCRs); design of computer databases; updating of database software; data warehousing; provision of information and data relating to medical research and development; rendering of computer graphics featuring digital image correction for research and development; computer graphic design services featuring data and image processing services for making three dimensional models; non-medical graphic design featuring digital imaging services; optical imaging for use in research and development of medicines; imaging via computers for use in research and development of medicines; graphic design services for generating and processing data and images for making three dimensional models for use in research and development of medicines; none of the foregoing services for vitamin supplementsfor vitamin supplements or generic pharmaceuticals dispensed by prescriptionfor vitamin supplements or generic pharmaceuticals distributed to pharmacies or wholesale distributors selling to pharmacies
Publicações
Histórico de despachos e eventos da marca no USPTO.
34 publicações encontradas
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
13/07/2026
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
12/07/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
24/06/2026
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
24/03/2026
R.PR
REGISTERED-PRINCIPAL REGISTER
24/03/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/02/2026
PUBO
PUBLISHED FOR OPPOSITION
03/02/2026
GPNX
NOTIFICATION PROCESSED BY IB
29/01/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
28/01/2026
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
14/01/2026
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
13/01/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/01/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/12/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/12/2025
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
05/12/2025
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
27/10/2025
GNFR
FINAL REFUSAL E-MAILED
27/10/2025
CNFR
FINAL REFUSAL WRITTEN
27/10/2025
CORR
CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
12/08/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/06/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/06/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/06/2025
RFNT
REFUSAL PROCESSED BY IB
22/02/2025
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
14/02/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
06/02/2025
RFRR
REFUSAL PROCESSED BY MPU
06/02/2025
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
31/01/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
01/01/2025
CNRT
NON-FINAL ACTION WRITTEN
31/12/2024
DOCK
ASSIGNED TO EXAMINER
30/12/2024
MAFR
APPLICATION FILING RECEIPT MAILED
27/09/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
27/09/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
26/09/2024
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace MULTIGEN ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.